Table 1

Baseline demographics, overview of antibiotic courses, outcome variables
Phase I (91 days) Phase II (110 days) p-value
Admissions 174 185 0.48
Hospitalisation days 952 1186 0.84
Hospitalisation days / admissiona 5.47 (1/3/41) 6.41 (1/3/71) 0.24
Fatal casualities 0 3 0.25
Infection-related fatal casualities 0 0 1
Sex (% male) 58% 60.5% 0.23
Age at admissionb 6 mt (0–16 yrs) 7 mt (0–16 yrs) 0.48
Cardiosurgery admissions 67.8% 57.8% 0.05
Cardiology admissions 13.2% 20.5% 0.06
Respiratory admissions 10.3% 13.5% 0.35
Other admissionsc 8.6% 8.1% 0.86
Antibiotic courses total 194 182 0.14
Prophylaxis courses 66.5% 55.5% 0.02*
Non-proven infection courses 27.3% 31.3% 0.39
Proven infection courses 6.2% 13.2% 0.02*
Secondary antibiotic courses total 8.2% 6% 0.59
Secondary courses for prophylaxis 2.1% 1.1% 0.68
Secondary courses for non-proven infection 4.1% 4.4% 0.90
Secondary courses for proven infection 2.1% 0.5% 0.37
Infection relapse rate (non-proven + proven) 6.2% 5.0% 0.62

Baseline demographics. *statistically significant, amean (min/median/max), bmedian (min-max), cgeneral paediatric surgery, ENT, thoracic surgery.

Stocker et al.

Stocker et al. BMC Pediatrics 2012 12:196   doi:10.1186/1471-2431-12-196

Open Data